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overview
Epithelial ovarian cancer has a very high rate of relapse after primary therapy; historically approximately 70%
of patients with a complete clinical response to surgery and adjuvant chemotherapy will relapse and die of the
disease. Although this number has slowly improved, cure rates remain less than 50%. As such, maintenance
therapy with the aim of preventing or delaying disease relapse and the goal of improving overall survival has
been the subject of intense study. Numerous earlier studies with agents ranging from radioactive phosphorus
to extended frontline therapy or to monthly taxol administration demonstrated encouraging improvements in
progression-free survival (PFS) only to ﬁnd, disappointingly, no beneﬁt in overall survival. In addition, the PFS
advantage of maintenance therapy was associated with disconcerting side effects such that maintenance
therapy was not adapted as standard of care. Studies with bevacizumab and PARP inhibitors have dem-
onstrated a PFS advantage with a manageable side-effect proﬁle. However, an overall survival advantage
remains unclear, and the use of these approaches thus remains controversial. Furthermore, in recurrent
disease, the length of chemotherapy and beneﬁts of extended chemotherapy is unclear. Thus, additional trials
assessing maintenance strategies in ovarian and other gynecologic malignancies are needed.
MAINTENANCE STRATEGIES IN GYNECOLOGIC
CANCERS, TRIAL DESIGN, AND ENDPOINTS
The optimal duration of treatment with chemotherapy,
targeted agents, or maintenance strategies in gyne-
cologic malignancies remains to be determined in
some settings. Contemporary maintenance strategies
can incorporate either a new agent (switch mainte-
nance) or maintain a component of the initial treatment
following the standard duration (continuation mainte-
nance).1-7 Maintenance strategies are typically re-
stricted to patients who achieve a partial response
(PR), complete response (CR), or at least stable dis-
ease following initial treatment.
As illustrated in Fig. 1, two different trial designs have
been used to assess maintenance therapy in gyne-
cologic cancers. The switch-maintenance trial design
incorporates the investigational drug versus placebo at
the end of standard chemotherapy. This scenario thus
selects only those patients who respond to standard-
of-care therapy.5,6,8,9 Recent studies with PARP in-
hibitors are good examples of this study design in
epithelial ovarian cancer (EOC). The other primary
approach, called continuation maintenance, includes
the maintenance agent in the primary treatment. Trials
assessing bevacizumab in EOC incorporated bev-
acizumab into the induction chemotherapy phase
followed by maintenance bevacizumab.10-13 When
bevacizumab was examined in cervical cancer, it was
incorporated into initial chemotherapy until progres-
sion, unacceptable toxicity, or CR and did not in-
corporate a maintenance strategy with the drug as part
of the study.14
The current gold standards for assessing efﬁcacy of novel
agents are overall survival (OS) and quality of life (QOL),
but PFS has been used to argue for drug use and ap-
proval.1,15 Different QOL assessments have been in-
corporated into maintenance clinical trials in gynecologic
cancers, including the European Quality of Life–5 Di-
mensions tool, which measures a patient’s perceived
health state in ﬁve domains (mobility, self-care, usual
activities, pain/discomfort, and anxiety/depression).16
The Functional Assessment of Chronic Illness Therapy
(FACIT) tool has speciﬁc cancer site–adjusted ques-
tionnaires and also includes assessments of physical,
social/family, emotional, and functional well-being.17-19 In
fact, changes in FACIT scores from baseline can be
measured through the Trial Outcome Index (TOI) score.17
Other useful QOL assessments that have been in-
corporated into maintenance trials are quality-adjusted
PFS and time without symptoms and toxicity9; however,
difﬁculties in effectively assessing QOL and the feasibility
of recording OS (larger sample and longer follow-up) led
to the incorporation of other time-to-event endpoints
(Fig. 2) as follows.
First, PFS is extensively used as the primary endpoint
in maintenance trials in gynecologic cancers.5,8,20 One
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of the beneﬁts of using PFS is the lack of confounding by
subsequent lines of treatment, and PFS is often used as
a surrogate of OS in EOC.21 It is important to note that the
association of PFS with OS in the contemporary oncology
era must be done with caution, as most published literature
outside of colorectal cancer and EOC has not supported this
surrogacy.15
Second, although subsequent increasingly toxic therapy
may be delayed, a PFS improvement does not always
correlate with an improved QOL because treatment-related
toxicity and convenience must be kept in mind.1,15 In fact,
PFS should not be used as the main endpoint for the ap-
proval of a new treatment if clinical beneﬁt is not demon-
strated.1 The American Society of Clinical Oncology Value
Framework and the European Society of Medical Oncology
Magnitude of Clinical Beneﬁt Scale are validated tools that
stratify the magnitude of clinical beneﬁt of new drugs and
help physicians deliver cost-effective cancer care.22,23 In the
recurrent ovarian cancer setting, the Fifth Ovarian Cancer
Consensus Conference established that PFS must be
PRACTICAL APPLICATIONS
• The data support the use of maintenance ola-
parib in those with a mutation (somatic or
germline) in BRCA1/2. Somatic and germline
BRCA1/2 testing needs to be incorporated from
the initial clinic visit in order to have this in-
formation at the appropriate time.
• For women with advanced ovarian cancer,
particularly those with stage IV, bevacizumab as
maintenance treatment has shown to improve
progression-free survival (PFS), as well as
overall survival (OS) in high risk-patients, and
should be considered.
• Women with BRCA mutations who achieve
a partial or complete response to ﬁrst-line
therapy should be treated with PARP inhibitor
maintenance therapy with olaparib (SOLO1).
• For women with recurrent ovarian cancer who
respond to repeat treatment with a platinum-
based regimen, maintenance treatment with
a PARP inhibitor consistently improves PFS
compared to no maintenance treatment. This
beneﬁt was seen in this population regardless of
BRCA1/2 mutation status.
• For women with recurrent or metastatic cervical
cancer, chemotherapy plus bevacizumab is
associated with an improvement in overall
survival compared to chemotherapy alone. For
those who discontinue chemotherapy, contin-
uation of bevacizumab remains a reasonable
strategy.
A CONTINUATION- MAINTENANCE 
B SWITCH- MAINTENANCE WITH A GAP
.
C THREE-ARM DESIGN
D NO MAINTENANCE 
FIGURE 1. Trial Designs Used to Assess Maintenance Therapy in
Gynecologic Cancers
(A) Continuation maintenance. (B) Switch maintenance: maintenance
with a gap. (C) Three-arm design. (D) No maintenance.
Abbreviations: CR, complete response; R, randomized; PD, progressive
disease; PR, partial response.
Adapted fromMarkman et al2 (A), Moore et al8 (B), Burger et al12 (C), and
Tewari14 et al (D).
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supported by clinical beneﬁt.24 It was also agreed that OS is
the preferred endpoint when median OS is expected to be
less than 12 months, whereas PFS supported by additional
measurements of clinical beneﬁt is the preferred endpoint
when median OS is more than 12 months.
Third, time from the patient’s random assignment to pro-
gression while receiving second-line therapy (PFS2) or
death may be a better surrogate of the effect of maintenance
treatment, because it reﬂects disease control and mainte-
nance effects in subsequent lines.1
Finally, time to ﬁrst subsequent therapy (TFST) or death and
time to second subsequent therapy or death (TSST) assess
the time from study treatment randomization to the start
date of the ﬁrst and second subsequent anticancer thera-
pies, respectively. TSST can also be approximated to PFS2,
and it is especially useful when regular tumor assessment
until the time of second progression is not feasible.1
Cost-effectiveness analysis provides a standard technique
to estimate the cost relative to health gains of a new in-
tervention, such as the incorporation of a maintenance
treatment.25 One approach to addressing this question is the
incremental cost-effectiveness ratio, which calculates the
ratio of the costs to the effectiveness of two medical in-
terventions and is expressed as cost per unit of the measure
of effect (where cost is expressed in terms of monetary units
and effects can be measured in terms of health status or
another outcome of interest).25 Although no formal will-
ingness-to-pay threshold is currently used for health in the
United States, $100,000 to $150,000 USD per quality-
adjusted life-year is used as a reference.26 Besides clini-
cal beneﬁt, treatment-related toxicity, and QOL impact,
cost-effectiveness must be recognized as an important
factor by regulatory agencies to select the appropriate
treatment strategies.7
OVARIAN CANCER
Approximately 90% of all ovarian cancers are epithelial and
can be divided into ﬁve distinct histologic subtypes: high-grade
serous ovarian cancer (HGSOC), low-grade serous ovarian
cancer (LGSOC), endometriod, clear cell, and muscinous
ovarian cancers.27,28 Of these, approximately 70% are the
HGSOC histologic type and are diagnosed in advanced stages
(III/IV).27,28 Maintenance trials assessing PARP inhibitors have
predominantly included patients with HGSOC (a small number
of patients with high-grade endometrioid cancer were also
included),5,6,9,29 whereas most EOC subtypes are included in
trials assessing bevacizumab (carcinosarcoma was excluded
in ICON7).11,13 Although the histologic subtype of ovarian
cancer should be considered as a stratiﬁcation criterion for
clinical trials, this remains a challenge in treatment access in
rare cancer subtypes.24
The Role of Consolidation/Maintenance Therapy Following
Adjuvant Therapy
Phase III trials comparing adjuvant treatment with either car-
boplatin/paclitaxel or cisplatin/paclitaxel following debulking
surgery have incorporated six cycles of treatment.30,31
The administration of six cycles of chemotherapy with
carboplatin and paclitaxel has become standard practice for
women with advanced ovarian cancer, although some
trials have suggested that fewer cycles might be just as
effective.32-34 Three randomized trials compared ﬁve to six
cycles with eight, 10, and 12 cycles, showing no beneﬁt of
continuation of the treatment beyond ﬁve or six cycles.35 As
discussed below, several strategies have been explored
following frontline chemotherapy treatment, includ-
ing consolidation or maintenance chemotherapy, anti-
angiogenics, and PARP inhibitors. The role of maintenance
immune-checkpoint inhibitors alone or in combination is
currently being explored in clinical trials (NCT02718417).
Compared with hematologic malignancies, the role of
maintenance or consolidation chemotherapy in ovarian
cancer is limited because no survival advantage has been
found with this strategy to date.36 The ﬁrst trial to demon-
strate an improvement in PFS with maintenance chemo-
therapy was the SWOG-9701/GOG-178 phase III study
of either three or 12 cycles of single-agent paclitaxel
FIGURE 2. Time-to-Event Endpoints
Abbreviations: CR, complete
response; PR, partial response;
R, randomized; PD, progressive
disease; PFS, progression-free
survival; TFST, time to ﬁrst
subsequent therapy or death;
PFS2, progression while re-
ceiving second-line therapy;
TSST, time to second sub-
sequent therapy or death.
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administered every 28 days to patients who had achieved
a CR to primary platinum/paclitaxel-based chemotherapy.2
In an updated analysis, the median PFS was 22months with
12 cycles versus 14months with three cycles (p = .006), but
there remained nodifference inOS (53 vs. 48months, p= .34).3
A more recent phase III study (GOG-212, NCT00108745)
evaluated a year of monthly maintenance chemotherapy with
paclitaxel, the paclitaxel conjugate CT-2103, or observation after
CR to primary cytotoxic chemotherapy. The study ﬁndings
showed a 5.5-month prolongation of PFS with paclitaxel treat-
ment versus observation but no improvement in OS.37 A
Cochrane Collaboration meta-analysis of eight randomized trials
in which maintenance chemotherapy, with either cisplatin,
anthracyclines, paclitaxel, or the combination of cisplatin and
doxorubicin, given following remission showed no evidence of
improvement in OS or PFS.38 The extended chemotherapy was
associated with an increased risk of cumulative toxicity.38
First-line maintenance antiangiogenics Bevacizumab,
a humanized anti-VEGF monoclonal antibody, was the ﬁrst
drug licensed for maintenance therapy in ovarian cancer.
Two trials have shown notable improvement in PFS when
bevacizumab is given with ﬁrst-line carboplatin and paclitaxel
chemotherapy and then continued as maintenance
therapy (Fig. 1).11,12 An OS advantage for bevacizumab
has been seen but may be restricted to patients with stage
IV disease.
In ICON7 (NCT00483782), patients with histologically
conﬁrmed, high-risk, early (International Federation of
Gynecology and Obstetrics [FIGO] stage I or IIA with clear
cell or grade 3 tumors) or advanced-stage (FIGO stage IIB to
IV) EOC (n = 1,528) were randomly assigned to receive
standard carboplatin and paclitaxel chemotherapy or to the
same regimen plus bevacizumab (7.5 mg/kg), given con-
currently every 3 weeks for ﬁve or six cycles and continued
monthly for 12 additional maintenance cycles or until dis-
ease progression occurred in the bevacizumab group.11 In
the GOG-0218 study (NCT00262847), treatment-naı¨ve
patients with incompletely resectable stage III or any
stage IV EOC (n = 1,873) were randomly assigned (1:1:1) to
carboplatin plus paclitaxel without bevacizumab (15 mg/kg),
carboplatin plus paclitaxel with bevacizumab for up to six
cycles, or carboplatin plus paclitaxel with bevacizumab for six
cycles followed by single-agent bevacizumab for up to 15
additional doses.12 There were notable population differences
in both studies. Whereas ICON7 included patients with early-
stage high-risk cancer, GOG-0218 only included patients
with stage III to IV disease. Moreover, patients were included
in ICON7 regardless of the presence of residual disease in
initial surgery, whereas only those patients with incompletely
resected disease were eligible for inclusion in GOG-0218
(there was a protocol amendment to allow inclusion of pa-
tients with stage III residual disease of, 1 cm). Both studies
showed that administration of bevacizumab during and
following primary chemotherapy offered a modest beneﬁt in
PFS of 2 months in ICON7 (hazard ratio [HR], 0.93; p = .25)
and 4 months in GOG-0218 (HR 0.72; p , .001).11,12,39
In ICON7, no OS beneﬁt of bevacizumab was recorded
(median OS of 58.6 vs. 58 months in the standard che-
motherapy group vs. the bevacizumab group; HR 0.99;
95% CI, 0.85–1.14; p = .85).39 A predeﬁned subgroup
analysis of 502 patients with poor prognosis disease (FIGO
stage III with residuum . 1 cm, any FIGO stage IV, or no
debulking surgery) showed a signiﬁcant difference in OS
between women who received bevacizumab plus chemo-
therapy and those who received chemotherapy alone
(median OS of 30.2 months with standard chemotherapy vs.
39.7 months with bevacizumab; HR 0.78; 95% CI, 0.63–
0.97, p = .03).39 Additional analysis has shown a PFS beneﬁt
from bevacizumab in all subgroups explored, which was
greatest in the high-risk group (HR 0.73; p = .001).39,40
In the GOG-0218 study, the estimated median PFS was
10.3 months for patients receiving chemotherapy without
bevacizumab compared with 14.1 months for patients re-
ceiving bevacizumab with chemotherapy followed by single-
agent bevacizumab (HR 0.72; 95% CI, 0.62–0.82; p ,
.001).12 In an analysis where patients with increased CA125
levels were censored (as requested by regulatory authori-
ties), PFS was 12 months in the control group and 18
months in the maintenance bevacizumab arm (HR 0.64;
p, .001).12 As reported by Burger et al,41 no differences in
OS were found in the overall population (HR 0.96; 95% CI,
0.85–1.09; p = .53) but ﬁnal publication of the study results
is awaited.12,41 For patients with stage IV disease, median
OS was 32.6 months in the chemotherapy arm and 42.8
months in the maintenance bevacizumab arm (HR 0.774;
p value not reported).
Figure 3 illustrates bevacizumab approval by the European
Medicines Agency (EMA) and the U.S. Food and Drug
Administration (FDA). Given the potential impact of bev-
acizumab on OS, it is important to also know the drug’s
effects on QOL. In ICON7, the mean global QOL score at
54 weeks was higher in the standard chemotherapy group
than in the bevacizumab group (mean6 SD of 76.16 18.2
vs. 69.7 6 19.1 points; difference, 6.4 points; 95% CI,
3.7–9.0, p, .0001).42 However, in GOG-0218, bevacizumab
compromised QOL, as measured by the TOI score, to a mild
extent during chemotherapy but had no prolonged effect
after chemotherapy completion.12 GOG-0218 participants
received bevacizumab or placebo every 3 weeks, whereas
no placebo was given in ICON7. The reduction in QOL
during maintenance bevacizumab seen in ICON7 and not
observed in GOG-0218 may be attributable to patient at-
tendance for infusions every 3 weeks in the bevacizumab
and placebo arms in GOG-0218, rather than only in
the bevacizumab arm as in ICON7. The observation that
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GOG-0218 participants showed no deterioration in QOL during
maintenance bevacizumab suggests that toxicity of mainte-
nance bevacizumab has minimal impact on QOL.12 Unlike
chemotherapy and PARP inhibitors, the majority of patients
receiving bevacizumab have minimal symptomatic side
effects.43,44 Pain is one of the more common therapy-related
symptoms for patients taking bevacizumab than placebo; for
many patients, this is manifested as joint or muscle pain.
Gastrointestinal perforation/ﬁstula is a rare but serious adverse
event for patients with advanced disease involving the bowel.44
Two oral antiangiogenic agents have shown signiﬁcant im-
provement in PFS as maintenance therapy with no OS ad-
vantage. First-line maintenance treatment with pazopanib
showed an improvement in PFS (17.9 vs. 12.3 months; HR
0.77; 95% CI, 0.64–0.91; p = .002), with a 33% treatment
discontinuation rate attributable to toxicity.45 Although a cat-
egory IIb recommendation in the National Comprehensive
Cancer Network Guidelines, this has not been licensed for
use in ovarian cancer. Frontline nintedanib improved PFS by
less than 1 month (17.2 vs. 16.6 months; HR 0.84; 95% CI,
0.72–0.98; p = .024) and is not marketed.46
Paclitaxel administered weekly has a potential anti-
angiogenic effect.47 In the GOG-262 trial (NCT01167712),
patients who received weekly paclitaxel plus 3-weekly
carboplatin but not bevacizumab had a 3.9-month im-
provement in PFS compared with those who received
3-weekly chemotherapy. However, there was no improvement
in PFS in the weekly arm if bevacizumab was given to both
arms.48 Dose-dense paclitaxel administration (without bev-
acizumab) showed a PFS and OS beneﬁt in a Japanese
population.49 However, no beneﬁt of this approach was found
in European trials, possibly owing to pharmacogenomic in-
ﬂuences. When weekly paclitaxel and 3-weekly carboplatin
was compared with standard 3-weekly chemotherapy in the
ICON-8 study (NCT01654146), no differences in PFS were
found (17.9 vs. 20.6 months in the 3-weekly arm vs. the
weekly paclitaxel arm; HR 0.92; p = .45).50 In theMITO7 trial,
carboplatin and paclitaxel were both administered weekly,
with a lower-dose intensity of paclitaxel, and showed no
differences in PFS compared with the 3-weekly regimen
(17.3 vs. 18.3 months for 3-weekly treatment vs. the weekly
regimen; HR 0.96; 95% CI, 0.8–1.16; p = .66).51 The
suggestion that administering frontline weekly paclitaxel is
equivalent to adding bevacizumab has not been proven.
Maintenance PARP inhibitors The randomized phase III
SOLO1 trial (NCT01844986) assessed maintenance
olaparib/placebo treatment following ﬁrst-line platinum-based
chemotherapy without bevacizumab.8 Eligible patients had
FIGURE 3. Drugs Approved by the European Medicines Agency and U.S. Food and Drug Administration for Treatment of Gynecologic Cancers
Abbreviations: EMA, EuropeanMedicines Agency; FDA, U.S. Food and Drug Administration; PARPi, PARP inhibitor; EOC, epithelial ovarian cancer; PlatS,
platinum sensitive; PlatR, platinum resistant.
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stage III and IV HGSOC or endometrioid ovarian cancer with
germline or somatic BRCAm (g/sBRCAm) and a PR or CR to
frontline chemotherapy. Most of the women had germline
BRCAm (gBRCAm) and a CR to frontline treatment. Patients
who had no evidence of disease stopped treatment after
2 years of treatment completion. The primary trial endpoint
was PFS assessed by the investigator. The risk of disease
progression at 3 years was signiﬁcantly lower in the olaparib
arm compared with placebo (rate of freedom from disease of
60% vs. 27% in the olaparib arm vs. the placebo arm; HR
0.3; 95% CI, 0.23–0.41; p , .001).8 PFS2 at 3 years was
also signiﬁcantly better in the olaparib arm (rate of freedom
from PFS2 of 75% vs. 60% in the olaparib arm vs. the
placebo arm; HR 0.50; 95% CI, 0.35–0.72; p , .001). The
OS data are still immature (21% of maturity), but no sig-
niﬁcant differences have been found thus far (HR 0.95;
95% CI, 0.6–1.53). Serious adverse events were considered
manageable and occurred for 22% of patients in the ola-
parib arm and 12% in the placebo arm, with anemia being
the most commonly reported. As reported in other PARP
inhibitor studies, acute myeloid leukemia occurred for 1%
of the patients receiving olaparib.8 QOL was assessed with
the ovarian cancer–speciﬁc FACT (Functional Assessment
of Cancer Therapy) questionnaire. The QOL TOI score
remained stable in the olaparib arm and decreased in the
placebo arm (group difference in change, −3 points; 95%
CI, −4.78 to −1.22) but was not considered clinically
meaningful.8
PFS and PFS2 results are outstanding for the advanced
ovarian cancer setting; however, QOL differences are not
clinically notable and long-term analysis is warranted to
explore the impact of frontline PARP inhibitor maintenance
on OS for BRCA1/2m carriers. Cost-effectiveness analysis
is also pending. Frontline maintenance olaparib treatment
was approved by the FDA in December 2018 for BRCAm
carriers (Fig. 3).
Platinum-Sensitive Recurrence
Antiangiogenics In the OCEANS trial (NCT00434642),
patients with platinum-sensitive recurrent EOC and mea-
surable disease were randomly assigned to carboplatin and
gemcitabine in combination with bevacizumab/placebo for
six to 10 cycles, followed by maintenance bevacizumab/
placebo until disease progression or unacceptable toxicity.13,52
The bevacizumab arm showed PFS beneﬁt compared with
placebo (12.4 vs. 8.4 months; HR 0.484; 95% CI, 0.388–
0.605; p, .0001). There were no notable differences in OS.13,52
The GOG-0213 phase III trial (NCT00565851) conﬁrmed
beneﬁt of bevacizumab in combination with carboplatin and
paclitaxel among platinum-sensitive patients, with a trend to-
ward OS beneﬁt (HR 0.829; p = .056).53
Cediranib, an oral pan-VEGF receptor tyrosine kinase in-
hibitor given as maintenance therapy, improved PFS by
2.3 months for patients with relapsed disease (8.7 vs. 11
months; HR 0.56; p , .0001), with a nonsigniﬁcant
improvement in OS (19.9 vs. 27.3 months; HR 0.85;
p = .21).54,55 Cediranib is not marketed but is undergoing
trials in combination with olaparib.
Retreatment with bevacizumab in the ﬁrst platinum-
sensitive relapse setting after progression to frontline
bevacizumab maintenance showed PFS beneﬁt (8.8 vs.
11.8 months; HR 0.51; p, .001) but not OS beneﬁt (HR 1;
p = .98).56 Treatment-related toxicity was as expected and in-
cluded reports of grade 3 hypertension or greater (27.5% vs.
9.7%; p , .001) and proteinuria (4% vs. 0%, p = .007),
which were more frequent in the bevacizumab arm.
PARP inhibitors Study 19 (NCT00753545) is a pivotal
registration randomized phase II trial assessing the switch-
maintenance strategy with olaparib/placebo for patients with
HGSOC treated with at least two prior lines of platinum-
based chemotherapy and response to the last treatment.
The primary study endpoint was PFS, which was signiﬁ-
cantly longer in the olaparib arm than in the placebo arm
(8.4 vs. 4.8 months; HR 0.35; 95% CI, 0.25–0.49; p, .001).57
Although the trial was not powered to assess OS, no sta-
tistically signiﬁcant differences were found (HR 0.73; 95%
CI, 0.55–0.96; p = .025; required threshold, p, .0095).58 A
preplanned retrospective analysis of the data by BRCAm
status showed that 51% of patients harbored a g/sBRCAm.29
An exploratory analysis demonstrated a longer PFS in
BRCAmcarriers (HR 0.18; p, .0001), pointing outBRCAm
as a response biomarker. Regarding QOL, no notable
changes in TOI, FACT–Ovarian Cancer, or FACT–Ovarian
Cancer Symptom Index questionnaire scores were found.57
A randomized open-label phase II trial, Study 41
(NCT01081951), assessed the effect of olaparib as a
continuous-maintenance strategy in platinum-sensitive re-
current HGSOC, with or without BRCAm.59 Patients were
randomly assigned to receive olaparib in combination with
carboplatin and paclitaxel followed by maintenance ola-
parib, or carboplatin and paclitaxel alone. Women receiving
olaparib had an improvement in PFS of 12.2 months in the
combination arm compared with 9.6 months PFS in the
chemotherapy-only arm (HR 0.51; 95% CI, 0.34–0.77; p =
.012), with the greatest beneﬁt seen for BRCAm carriers.
Although the study was not designed to measure the
contribution of each treatment, the late separation of the
PFS curves suggested that improvement was mainly at-
tributable to the maintenance phase. The treatment was
well tolerated, and adverse events were 10%more common
in the combination phase in the olaparib arm.59
The randomized phase III SOLO2/ENGOT-Ov21 trial
(NCT01874353) assessed olaparib/placebo as a switch-
maintenance treatment for patients with platinum-
sensitive HGSOC or endometrioid ovarian cancer with
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gBRCAm.9 The primary study endpoint was investigator-
assessed PFS, which was signiﬁcantly longer in the olaparib
arm (19.1 vs. 5.5 months; HR 0.3; 95% CI, 0.22–0.41; p,
.0001). PFS2 (HR 0.5; p, .0002), time to ﬁrst subsequent
therapy or death (HR 0.28; p, .0001), and TSST (HR 0.37;
p, .0001) also favored the olaparib arm. OS data were still
immature but again showed no signiﬁcant difference (HR
0.8; p = .43). Similarly, regarding QOL, there were no sig-
niﬁcant differences in TOI scores.
The randomized phase III ENGOT-OV16/NOVA trial
(NCT01847274) assessed niraparib/placebo switch main-
tenance for women with platinum-sensitive recurrent
HGSOC or ovarian cancer with BRCAm and response to the
last platinum-based chemotherapy.5 The study included
two independent cohorts, patients with gBRCAm (37%) and
those without gBRCAm. Homologous recombination de-
ﬁciency (HRD) was assessed with the Myriad myChoice
HRD test (Myriad Genetics, Salt Lake City, UT). PFS was
signiﬁcantly longer in the niraparib arm versus the placebo
arm in all prespeciﬁed cohorts, including the gBRCAm
cohort (21 vs. 5.5 months; HR 0.27; 95% CI, 0.17–0.41;
p, .001), the nongermline BRCAm cohort with HRD (12.9
vs. 3.8 months; HR 0.38; 95% CI, 0.24–0.59; p , .001),
and the gBRCA wild-type cohort (9.3 vs. 3.9 months; HR
0.45; 95% CI, 0.34–0.61; p , .001).5 Preliminary data
showed a beneﬁt in PFS2 in the gBRCAm (HR 0.48; p =
.006) and nongermline BRCAm (HR 0.69; p = .03) cohorts.
OS and TSST data have not yet been reported.5 Adverse
events and PFS were similar among patients older than age
70.60 QOL was assessed through the FACT–Ovarian Cancer
Symptom Index and European Quality of Life–5 Dimensions
questionnaires but did not show any notable differences
across the two groups.61
The randomized phase III ARIEL3 trial (NCT01968213)
assessed rucaparib/placebo maintenance therapy in
platinum-sensitive, HGSOC, or endometrioid ovarian cancer
with response to the last treatment. Loss of heterozygosity
was used as a marker of HRD through the Foundation
Medicine T5 NGS tool (Foundation Medicine, Cambridge,
MA). Patients in the rucaparib arm demonstrated an in-
crease in PFS in all prespeciﬁed subgroups compared with
placebo, including g/sBRCA1/2m carriers (16.6 vs. 5.4
months; HR 0.23; 95% CI, 0.16–0.34; p, .0001), patients
with HRD (13.6 vs. 5.4 months; HR 0.32; 95% CI, 0.24–0.
42; p , .0001), and the intention-to-treat population (10.8
vs. 5.4 months; HR 0.36; 95% CI, 0.30–0.45; p , .0001).6
In this study, PFS2 and TSST have not yet been analyzed
and patient-reported outcomes have not been published.
Although there is a PFS beneﬁt associated with mainte-
nance PARP inhibitors in platinum-sensitive recurrence, OS
beneﬁt remains to be deﬁned.43 Figure 3 illustrates EMA
and FDA approvals of PARP inhibitors for use in treating
EOC.62-67
Unlike non–small cell lung cancer trials in which EGFR
inhibitors were initially given to a large population and
subsequent studies were able to determine the biomarker
of response,68 initial ovarian cancer trials assessing
PARP inhibitors were initially restricted to women with
BRCA1/2m and the target population has subsequently
been expanding. In fact, theNOVA (NCT01847274) and ARIEL3
(NCT01968213) trials incorporated an assay to deﬁne
patients with HRD, but these studies were unable to ac-
curately predict who would beneﬁt from treatment.5,6
Currently, the FDA and EMA are not restricting ac-
cess to maintenance PARP inhibitors to BRCAm or HRD
carriers.64,65
Optimal treatment following PARP inhibitor maintenance,
retreatment with PARP inhibitors, and new combinations
with antiangiogenics are under investigation (e-VOLVE,
NCT02340611).69 In fact, several mechanisms of re-
sistance to PARP inhibitors have been reported, including
BRCA reversion mutations, nonhomologous end-joint repair
alterations, and mutations in genes that encode shieldin
subunits.70-72
Platinum-Resistant Recurrence
Antiangiogenics In the AURELIA trial (NCT00976911),
patients with platinum-resistant disease were randomly
assigned to either chemotherapy alone (pegylated liposomal
doxorubicin, topotecan, or weekly paclitaxel) or chemo-
therapy combined with 10mg/kg2 of bevacizumab weekly or
15 mg/kg every 3 weeks until progression or unacceptable
toxicity.20 The median PFS was 6.7 months in the combi-
nation arm compared with 3.4 months in the chemotherapy-
alone arm. Although no notable survival advantage was
detected, this could be because 40% of patients receiving
chemotherapy alone crossed over to receive bevacizumab on
progression. Themedian duration of therapy was three cycles
in the chemotherapy-alone arm versus six cycles in the
combined arm. In an exploratory analysis, the beneﬁt was
most pronounced in the weekly paclitaxel cohort.10More than
20% of AURELIA patients were still receiving therapy after 10
cycles.
As illustrated in Table 1, a Belgian analysis showed that
bevacizumab was more cost-effective when given ﬁrst line
than when given at relapse.73 Selecting patients with the
worse prognosis in both the GOG128 and ICON7 trials
improved the cost-effectiveness.
Intermittent treatment or chemotherapy holidays Paclitaxel is
one of the most active nonplatinum drugs used in mono-
therapy or in combination with bevacizumab in recurrent
platinum-resistant EOC.20,74,75 Although paclitaxel can be
administered every 3 weeks or weekly, the dose-dense
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weekly regimen is themost established in platinum-resistant
disease. There is a potential antiangiogenic effect with the
weekly regimen, although themechanism is still unknown.47
A Swedish randomized trial assessed paclitaxel mono-
therapy (weekly vs. every 3 weeks) in recurrent ovarian
cancer and failed to note any outcome differences between
the two administration types.76 The 3-weekly regimen was
associated with increased hematologic toxicity, arthralgia/
myalgia, and neuropathy, whereas the weekly regimen had
signiﬁcantly increased nail toxicity. Different durations and
schedules of weekly paclitaxel have been incorporated in
clinical trials in recurrent disease. For example, in the
AURELIA trial (NCT00976911), weekly paclitaxel was ad-
ministered until disease progression or unacceptable toxicity20
compared with topotecan, which was administered until
progression or for 6 months past the maximal response.74
Furthermore, in a GOG phase II trial (NCT00003160), pa-
tients could be switched to a schedule of 3 weeks on and
1 week off following the administration of 12 weeks of pac-
litaxel administered weekly with no break.75
The dose-dense regimen can be less convenient for the
patient, with weekly clinic visits. Both schedules are asso-
ciated with cumulative toxicity, including neurotoxicity, which
is the main cause of cancer disability.77 As a result, treatment
holidays or treatment-free periods have been introduced;
however, preclinical data suggest that longer taxane-free
intervals might be associated with treatment resistance.78,79
Ovarian cancer xenograft models have shown that continu-
ous administration of taxanes is associated with less treat-
ment resistance, including drug resistance–related genes
and drug efﬂux transporter expression, as well as reduced
tumor growth and proliferation.78,79
Pegylated liposomal doxorubicin has been used as mono-
therapy or in combination with bevacizumab in platinum-
resistant disease.20,80,81 The duration of pegylated liposomal
doxorubicin treatment remains controversial for patients
who have had a PR/CR after six cycles of therapy. For
example, in the AURELIA trial (NCT00976911), treat-
ment was administered until unacceptable toxicity or pro-
gression.20 Conversely, in a phase III trial comparing
pegylated liposomal doxorubicin with topotecan, treatment
was administered for up to 12months or continued further if
the patient had sustained clinical beneﬁt.80 In patients
receiving treatment for more than 12 consecutive months,
cumulative toxicities can include skin toxicity andmucositis,
and must be kept in mind.20,80,81 Risk of cardiac toxicity with
pegylated liposomal doxorubicin in EOC was reported to be
low.82,83
If patients have had no symptomatic beneﬁt or evidence of
response on serial CA125 measurements or scans after two
or three cycles, chemotherapy should be stopped. It is clear
that if a patient has responded to treatment but is developing
therapy-related toxicity, it is sensible to give the patient a rest
from the toxic therapy. However, it is unclear whether pa-
tients given a rest from therapy after evidence of symptom
beneﬁt having received three to six cycles would respond
again on reintroduction of the same therapy. Therapy could
be reintroduced after an agreed rest period or at ﬁrst de-
velopment of symptoms or on CA125 or scan evidence of
progression. It is possible that such an approach would be
as effective as maintenance therapy with improved QOL.
Further studies assessing the effect of treatment-free in-
tervals and their intermittent use are needed in EOC.
Hormonal Treatment
A recent meta-analysis of endocrine therapy in ovarian
cancer demonstrated a clinical beneﬁt rate of 41% among
2,490 patients in 53 trials, with a possibly greater effect
in low-grade tumors.84 Tamoxifen marginally appeared to
be the most active agent.84 The only randomized trial
conducted among mostly asymptomatic patients with
nonmeasurable disease and evidence of biochemical
progression following ﬁrst-line treatment (grades 1 and
2: 32.9%) was between thalidomide and tamoxifen and
showed signiﬁcantly improved OS in the tamoxifen arm (24
vs. 33.2 months for thalidomide vs. tamoxifen; HR 1.76;
95% CI, 1.16–2.68).85 Because hormonal treatment is well
tolerated and inexpensive, it has been considered a rea-
sonable option for women who would prefer some active
management as maintenance therapy or for an asymp-
tomatic rise in CA125 levels, over observation only.86
However, the results are confounded by the inclusion of
patients with LGSOC and other histologic subtypes.
LGSOCs are characterized by slow growth, relative che-
motherapy resistance, and higher estrogen and pro-
gesterone receptor expression.87,88 A retrospective study
showed that the administration of maintenance hormonal
TABLE 1. Comparison of Reported Cost-effectiveness by Trial Assessing Bevacizumab
GOG0128
GOG0128
(Stage 4) ICON7
ICON7
High Risk OCEANS AURELIA
Mean duration of bevacizumab treatment, weeks 41.93 35.7 42.99 NR 50.74 26.2
Mean OS HR 0.885 0.72 0.990 0.780 0.960 0.850
ICER (V/QALY gained) 157,816 51,931 443,027 82,277 587,182 172,370
Abbreviations: NR, not reported; OS, overall survival; HR, hazard ratio; ICER, incremental cost-effectiveness ratio; QALY, quality-adjusted life-year.
Maintenance Treatments and Chemotherapy Holidays in Gynecologic Cancers
2019 ASCO EDUCATIONAL BOOK | asco.org/edbook e159
Downloaded from ascopubs.org by University Health Network on May 23, 2019 from 205.189.058.087
Copyright © 2019 American Society of Clinical Oncology. All rights reserved.
treatment in stage II to IV LGSOC, following debulking
surgery and adjuvant chemotherapy, was associated with
PFS improvement (26.4 months for observation [95% CI,
21.8–31] vs. 64.9 months for hormonal maintenance [95%
CI, 43.5–86.3]; p , .001), but no signiﬁcant differences in
OS were found.89 This study requires prospective validation
as well as establishment of the optimal length of adjuvant
hormonal therapy.
OTHER GYNECOLOGIC CANCERS
Cervical Cancer
The optimal duration of ﬁrst-line platinum-based chemo-
therapy in metastatic or recurrent cervical cancer is still
unknown. Several GOG studies have assessed the role of
cisplatin combination chemotherapy for six cycles in
nonresponders or until disease progression or unac-
ceptable toxicity.90,91 Four different cisplatin-containing
doublets (cisplatin/paclitaxel vs. cisplatin/vinorelbine, cisplatin/
gemcitabine, and cisplatin/topotecan) were assessed in the
GOG-204 clinical trial (NCT00064077) for a maximum of six
cycles in nonresponders (including those with stable dis-
ease). Patients with an acceptable toxicity proﬁle and PR
were permitted to continue with the treatment after dis-
cussion with the study chair.92 No notable differences were
detected with respect to OS when cisplatin/paclitaxel was
compared with the three experimental regimens, but there
was a trend favoring the cisplatin (50 mg/m2) and paclitaxel
(135 mg/m2) combination, which emerged as standard of
care.92
The GOG-240 phase III clinical trial (NCT00803062) as-
sessed cisplatin/paclitaxel or topotecan/paclitaxel with or
without 15 mg/kg of bevacizumab through a two-by-two
factorial design as ﬁrst-line treatment in metastatic, per-
sistent, or recurrent cervical carcinoma (Fig. 1).14 Treatment
was administered until disease progression, unacceptable
toxicity, or CR. As such, no continuation maintenance with
bevacizumab was incorporated as part of this study. A
signiﬁcant improvement in OS (16.8 vs. 13.3 months; HR
0.77; 95% CI, 0.62–0.95; p = .0068) and in PFS (8.2 vs.
6 months; HR 0.68; 95% CI, 0.56–0.84; p = .0002) favoring
the bevacizumab-containing arms was found.93 Chemo-
therapy treatments with topotecan-paclitaxel were associ-
ated with a signiﬁcantly higher risk of progression (HR 1.39;
95%CI, 1.09–1.77) but not OS differences.14 The incidence
of ﬁstula was 14.5% in the bevacizumab arm (these patients
all received prior pelvic radiotherapy). There were no
substantial changes in QOL in the bevacizumab versus
nonbevacizumab arms.14
Bevacizumab has been the ﬁrst and only targeted treatment
granted approval for use in cervical cancer by regulatory
authorities after demonstrating clinically meaningful im-
provement in OS (Fig. 3).93 Despite the 3.5-month survival
advantage that bevacizumab demonstrated, it is important
to discuss potential side effects with patients, such as the
risk of ﬁstula, especially for women who have been treated
with prior pelvic radiotherapy. Although the number of
cycles was restricted to six in nonresponders in initial GOG
trials assessing cisplatin combinations, the GOG-240 trial
(NCT00803062) did not establish a preﬁxed number of
optimal cycles or a continuation-maintenance strategy with
bevacizumab. Given the risk of cumulative toxicity of cis-
platin and paclitaxel chemotherapy, including renal im-
pairment and neuropathy, clinicians often must stop the
chemotherapy treatment or stop one of the drugs soon after
six cycles have been delivered.77,94,95 The role of bev-
acizumab as a single-agent maintenance treatment has not
yet been explored as part of the GOG-240 clinical trial, and
this has led to concerns for regulatory agencies when only
single-agent bevacizumab is administered as maintenance
treatment.
Endometrial Cancer
Endometrial carcinoma There is substantial heterogeneity
within endometrial carcinomas. Although women with low-
grade endometrioid endometrial cancer tend to respond to
hormonal manipulation, those with high-grade tumors and
carcinosarcomas follow a more aggressive course and cy-
totoxic therapies are recommended.96,97 To date, no tar-
geted treatment beyond hormonal therapy has been
approved for use in endometrial cancer.97
Chemotherapy remains the main treatment for advanced
endometrial cancer. Doxorubicin, cisplatin, and paclitaxel
have been identiﬁed as active agents in endometrial cancer.98
The GOG has completed a series of phase III randomized
prospective trials of chemotherapy for advanced-stage or
recurrent endometrial carcinoma.98,99 The GOG177 phase
III randomized trial (NCT00698620) compared cisplatin,
doxorubicin, and paclitaxel to cisplatin and doxorubicin for
a maximum of seven cycles for women with advanced or
recurrent endometrial carcinoma. The three-drug regimen
was associated with an improved response rate (57% vs.
34%; p , .01), longer PFS (8.3 vs. 5.3 months; HR 0.60;
p , .01), and a slight improvement in OS (15.3 vs. 12.3
months; HR 0.75; p = .037) but signiﬁcantly increased
toxicity.100 The GOG-0209 phase III trial (NCT00063999)
compared the cisplatin, doxorubicin, and paclitaxel com-
bination with carboplatin and paclitaxel for seven cycles in
a noninferior design. The carboplatin and paclitaxel com-
bination was found to have fewer adverse events and higher
compliance and was not less effective than the three-drug
regimen.101 Although both GOG trials incorporated the
chemotherapy regimens for seven cycles, six are usually
administered in clinical practice.
No maintenance strategies are currently approved for en-
dometrial cancer. A phase II clinical trial assessed bev-
acizumab in combination with carboplatin and paclitaxel,
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followed by maintenance bevacizumab in advanced or
recurrent endometrial carcinoma with a maximum of one
prior chemotherapy regimen. Only 15 patients were en-
rolled; ﬁve CRs and six PRs were found, with an overall
response rate of 73% (CI, 45–91).102 Median PFS and OS
was 18 and 58 months, respectively. The trial was stopped
early because a competitive trial was scheduled to com-
mence.102 In a phase II trial (GOG-86P), the combination of
carboplatin and paclitaxel with bevacizumab followed by
maintenance bevacizumab until progression was compared
with historic controls, showing a signiﬁcant OS improvement
(HR 0.71; 92.2% CI, 0.33–0.91), with no differences in PFS
(HR 0.81; 92.2% CI, 0.63–1.02).103 A randomized phase II
trial evaluated carboplatin and paclitaxel for six cycles with
and without trastuzumab as a continuation-maintenance
treatment in high-grade serous endometrial cancer with
Her2/neu overexpression.104 The study demonstrated a
signiﬁcant improvement in PFS with the addition of tras-
tuzumab (8 vs. 12.6 months; HR 0.44; 90% CI, 0.26–0.76;
p = .005). Other trials with Her2-targeted agents are ongoing
in this population (NCT02491099). Her2 assessment should
routinely be incorporated in the treatment of high-grade
serous endometrial cancers.
Endometrial sarcoma As opposed to carcinomas, sarcoma
of the endometrium is rare and comprises less than 3% of all
endometrial malignancies, with an incidence of approxi-
mately one diagnosis per 100,000 women per year.105
Sarcomas are aggressive tumors with a high propensity to
metastasize, occur in younger individuals, and are com-
posed of several distinct histologic entities.105 Leiomyo-
sarcoma (LMS) is the most common (two-thirds of cases),
followed by endometrial stromal tumors, unclassiﬁed uter-
ine sarcoma, and adenosarcoma.105
Surgical resection without lymph node dissection and
without radiotherapy is standard for patients with primary
endometrial LMS.105 Because of high recurrence, a high
metastasis rate, and chemotherapy sensitivity, adjuvant
chemotherapy with doxorubicin and ifosfamide is consid-
ered for high-risk patients. The largest series to support
adjuvant chemotherapy is a meta-analysis of approximately
2,000 patients with high-grade soft-tissue sarcomas who
underwent surgical resection and were randomly assigned
to chemotherapy versus observation.106 Patients who re-
ceived chemotherapy with doxorubicin and ifosfamide had
the greatest beneﬁt in recurrence-free survival and OS.
Although this analysis included patients with LMS, it also
included patients with other types of sarcoma.106 Many
sarcoma centers prefer preoperative chemotherapy to
identify patients with chemotherapy-sensitive tumors, initi-
ate treatment of microscopic metastases earlier, and do not
operate on patients who are destined to develop metastatic
disease shortly after surgery.
There are currently no randomized data to support the use
of prolonged maintenance therapy in endometrial sarcomas
after resection or after response to chemotherapy. Active
chemotherapy agents include doxorubicin, ifosfamide,
dacarbazine, and gemcitabine but are generally not given
for prolonged periods of time without measurable disease
because of the risk of serious toxicities such as leukemia,
cardiomyopathy, and pneumonitis.107-109 However, endo-
metrial stromal tumors and low-grade LMS are more likely to
express the estrogen receptor, so there is a compelling
rationale to consider maintenance antiestrogen therapy for
these patients.105 Newer agents such as the multitargeted
kinase pazopanib and the drug trabectedin do not appear to
have serious toxicities when used for many years and thus
could also be considered for maintenance therapy for pa-
tients with exceptionally high risk.110,111 With so many active
systemic therapies, there is a compelling rationale for
a prospective trial of maintenance therapy in endometrial
LMS and potentially other sarcomas.
CONCLUSION
Maintenance strategies in ovarian cancer are incorporated
in clinical practice. Bevacizumab should be considered as
the frontline treatment for patients with high-risk cancer.11,12
PARP inhibitors have demonstrated a substantial in-
crease in PFS and PFS2 and should be considered as ﬁrst-
line maintenance treatment for BRCAm carriers8 as well as
in platinum-sensitive relapse regardless of BRCAm.5,6,9
However, caution is required because no OS beneﬁt has
been demonstrated yet with PARP inhibitors, and QOL
analyses across the different maintenance strategies have
not demonstrated beneﬁt.5,6,8,9,61 The addition of bev-
acizumab in cervical cancer does not incorporate a main-
tenance strategy as per the trial design, but it is the only
targeted treatment demonstrating OS beneﬁt in the overall
population thus far and cost-effectiveness is near current
willingness-to-pay standards.93,112 The optimal number of
cycles and chemotherapy schedules in recurrent platinum-
resistant ovarian cancer, cervical cancer, and endometrial
cancer remains controversial. In platinum-resistant, re-
current EOC, chemotherapy with or without breaks for
toxicity recovery should be tailored to each patient. Future
clinical trials examining the best treatment schedule are
warranted. The aim to ﬁnd the best treatment strategy has
led to an increased reliance on biomarkers, such as the
presence of HRD and loss of heterozygosity scores and
bevacizumab response predictive panels; however, with the
exception of BRCAm, none of these have been incorporated
as a determining treatment factor.5,6,39,113,114
Maintenance Treatments and Chemotherapy Holidays in Gynecologic Cancers
2019 ASCO EDUCATIONAL BOOK | asco.org/edbook e161
Downloaded from ascopubs.org by University Health Network on May 23, 2019 from 205.189.058.087
Copyright © 2019 American Society of Clinical Oncology. All rights reserved.
AFFILIATIONS
1Princess Margaret Cancer Centre, University Health Network, Toronto,
ON, Canada
2Mount Vernon Hospital, Northwood, UK
3UPMC Hillman Cancer Center, Pittsburgh, PA
4Sylvester Comprehensive Cancer Center, Miami, FL
CORRESPONDING AUTHOR
Amit M. Oza, MD, FRCP, Princess Margaret Cancer Centre, University
Health Network, ON M5G 2M9, Toronto, ON, Canada; email: amit.oza@
uhn.ca.
AUTHORS’ DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST
AND DATA AVAILABILITY STATEMENT
Disclosures provided by the authors and data availability (if applicable) are
available with this article at DOI https://doi.org/10.1200/EDBK_238755.
REFERENCES
1. Freidlin B, Little RF, Korn EL. Design issues in randomized clinical trials of maintenance therapies. J Natl Cancer Inst. 2015;107:djv225.
2. Markman M, Liu PY, Wilczynski S, et al.; Gynecologic Oncology Group. Phase III randomized trial of 12 versus 3 months of maintenance paclitaxel in patients
with advanced ovarian cancer after complete response to platinum and paclitaxel-based chemotherapy: a Southwest Oncology Group and Gynecologic
Oncology Group trial. J Clin Oncol. 2003;21:2460-2465.
3. Markman M, Liu PY, Moon J, et al. Impact on survival of 12 versus 3 monthly cycles of paclitaxel (175 mg/m2) administered to patients with advanced ovarian
cancer who attained a complete response to primary platinum-paclitaxel: follow-up of a Southwest Oncology Group and Gynecologic Oncology Group phase 3
trial. Gynecol Oncol. 2009;114:195-198.
4. Matulonis UA, Harter P, Gourley C, et al. Olaparib maintenance therapy in patients with platinum-sensitive, relapsed serous ovarian cancer and a BRCA
mutation: overall survival adjusted for postprogression poly(adenosine diphosphate ribose) polymerase inhibitor therapy. Cancer. 2016;122:1844-1852.
5. Mirza MR, Monk BJ, Herrstedt J, et al.; ENGOT-OV16/NOVA Investigators. Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer.
N Engl J Med. 2016;375:2154-2164.
6. Coleman RL, Oza AM, Lorusso D, et al.; ARIEL3 investigators. Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum
therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017;390:1949-1961.
7. Edelman MJ, Le Chevalier T, Soria JC. Maintenance therapy and advanced non-small-cell lung cancer: a skeptic’s view. J Thorac Oncol. 2012;7:1331-1336.
8. Moore K, Colombo N, Scambia G, et al. Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer. N Engl J Med. 2018;379:2495-2505.
9. Pujade-Lauraine E, Ledermann JA, Selle F, et al.; SOLO2/ENGOT-Ov21 investigators. Olaparib tablets as maintenance therapy in patients with platinum-
sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet
Oncol. 2017;18:1274-1284.
10. Poveda AM, Selle F, Hilpert F, et al. Bevacizumab combined with weekly paclitaxel, pegylated liposomal doxorubicin, or topotecan in platinum-resistant
recurrent ovarian cancer: analysis by chemotherapy cohort of the randomized phase III AURELIA trial. J Clin Oncol. 2015;33:3836-3838.
11. Perren TJ, Swart AM, Pﬁsterer J, et al.; ICON7 Investigators. A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med. 2011;365:2484-2496.
12. Burger RA, Brady MF, Bookman MA, et al.; Gynecologic Oncology Group. Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl
J Med. 2011;365:2473-2483.
13. Aghajanian C, Blank SV, Goff BA, et al. OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in
patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. J Clin Oncol. 2012;30:2039-2045.
14. Tewari KS, Sill MW, Long HJ 3rd, et al. Improved survival with bevacizumab in advanced cervical cancer. N Engl J Med. 2014;370:734-743.
15. Booth CM, Eisenhauer EA. Progression-free survival: meaningful or simply measurable? J Clin Oncol. 2012;30:1030-1033.
16. Janssen MF, Pickard AS, Golicki D, et al. Measurement properties of the EQ-5D-5L compared to the EQ-5D-3L across eight patient groups: a multi-country
study. Qual Life Res. 2013;22:1717-1727.
17. Webster K, Cella D, Yost K. The Functional Assessment of Chronic Illness Therapy (FACIT) measurement system: properties, applications, and interpretation.
Health Qual Life Outcomes. 2003;1:79.
18. Basen-Engquist K, Bodurka-Bevers D, Fitzgerald MA, et al. Reliability and validity of the functional assessment of cancer therapy-ovarian. J Clin Oncol. 2001;
19:1809-1817.
19. Janda M, Obermair A, Cella D, et al. Vulvar cancer patients’ quality of life: a qualitative assessment. Int J Gynecol Cancer. 2004;14:875-881.
20. Pujade-Lauraine E, Hilpert F, Weber B, et al. Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: the AURELIA open-
label randomized phase III trial. J Clin Oncol. 2014;32:1302-1308.
21. Bast RC, Thigpen JT, Arbuck SG, et al. Clinical trial endpoints in ovarian cancer: report of an FDA/ASCO/AACR public workshop. Gynecol Oncol. 2007;
107:173-176.
22. Schnipper LE, Davidson NE, Wollins DS, et al; American Society of Clinical Oncology. American Society of Clinical Oncology statement: a conceptual framework
to assess the value of cancer treatment options. J Clin Oncol. 2015;33:2563-2577.
23. Cherny NI, Dafni U, Bogaerts J, et al. ESMO-Magnitude of Clinical Beneﬁt Scale version 1.1. Ann Oncol. 2017;28:2340-2366.
Madariaga et al
e162 2019 ASCO EDUCATIONAL BOOK | asco.org/edbook
Downloaded from ascopubs.org by University Health Network on May 23, 2019 from 205.189.058.087
Copyright © 2019 American Society of Clinical Oncology. All rights reserved.
24. WilsonMK, Pujade-Lauraine E, Aoki D, et al.; Participants of the Fifth Ovarian Cancer Consensus Conference. Fifth Ovarian Cancer Consensus Conference of the
Gynecologic Cancer InterGroup: recurrent disease. Ann Oncol. 2017;28:727-732.
25. Bambha K, Kim WR. Cost-effectiveness analysis and incremental cost-effectiveness ratios: uses and pitfalls. Eur J Gastroenterol Hepatol. 2004;16:519-526.
26. Neumann PJ, Cohen JT, Weinstein MC. Updating cost-effectiveness--the curious resilience of the $50,000-per-QALY threshold. N Engl J Med. 2014;
371:796-797.
27. Ramalingam P. Morphologic, immunophenotypic, and molecular features of epithelial ovarian cancer. Oncology (Williston Park). 2016;30:166-176.
28. Kurman RJ, Carcangiu ML, Herrington CS. World Health Organisation Classiﬁcation of Tumours of the Female Reproductive Organs. Lyon, France: International
Agency for Research on Cancer; 2014.
29. Ledermann J, Harter P, Gourley C, et al. Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned
retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. Lancet Oncol. 2014;15:852-861.
30. Ozols RF, Bundy BN, Greer BE, et al.; Gynecologic Oncology Group. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients
with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol. 2003;21:3194-3200.
31. du Bois A, Lu¨ck HJ, Meier W, et al.; Arbeitsgemeinschaft Gyna¨kologische Onkologie Ovarian Cancer Study Group. A randomized clinical trial of cisplatin/
paclitaxel versus carboplatin/paclitaxel as ﬁrst-line treatment of ovarian cancer. J Natl Cancer Inst. 2003;95:1320-1329.
32. Bristow RE, Tomacruz RS, Armstrong DK, et al. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era:
a meta-analysis. J Clin Oncol. 2002;20:1248-1259.
33. Hakes TB, Chalas E, Hoskins WJ, et al. Randomized prospective trial of 5 versus 10 cycles of cyclophosphamide, doxorubicin, and cisplatin in advanced ovarian
carcinoma. Gynecol Oncol. 1992;45:284-289.
34. Lambert HE, Rustin GJ, Gregory WM, et al. A randomized trial of ﬁve versus eight courses of cisplatin or carboplatin in advanced epithelial ovarian carcinoma:
a North Thames Ovary Group study. Ann Oncol. 1997;8:327-333.
35. Bertelsen K, Grenman S, Rustin GJ. How long should ﬁrst-line chemotherapy continue? Ann Oncol. 1999;10(Suppl 1):17-20.
36. Amylon MD, Shuster J, Pullen J, et al. Intensive high-dose asparaginase consolidation improves survival for pediatric patients with T cell acute lymphoblastic
leukemia and advanced stage lymphoblastic lymphoma: a Pediatric Oncology Group study. Leukemia. 1999;13:335-342.
37. Copelanda LJ, Brady MF, Burger RA, et al. A phase III trial of maintenance therapy in women with advanced ovarian/fallopian tube/peritoneal cancer after
a complete clinical response to ﬁrst-line therapy: an NRG oncology study. Gynecol Oncol. 2017;145 (suppl; abstr 219).
38. Mei L, Chen H, Wei DM, et al. Maintenance chemotherapy for ovarian cancer. Cochrane Database Syst Rev. 2013;(6):CD007414.
39. Oza AM, Cook AD, Pﬁsterer J, et al.; ICON7 trial investigators. Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian
cancer (ICON7): overall survival results of a phase 3 randomised trial. Lancet Oncol. 2015;16:928-936.
40. Gonza´lez Martı´n A, Oza AM, Embleton AC, et al.; ICON7 investigators. Exploratory outcome analyses according to stage and/or residual disease in the ICON7 trial
of carboplatin and paclitaxel with or without bevacizumab for newly diagnosed ovarian cancer. Gynecol Oncol. 2019;152:53-60.
41. Burger RA, Enserro D, Tewari KS, et al. Final overall survival (OS) analysis of an international randomized trial evaluating bevacizumab (BEV) in the primary
treatment of advanced ovarian cancer: a NRG Oncology/Gynecologic Oncology Group (GOG) study. J Clin Oncol. 2018;36 (suppl; abstr 5517).
42. Stark D, Nankivell M, Pujade-Lauraine E, et al. Standard chemotherapy with or without bevacizumab in advanced ovarian cancer: quality-of-life outcomes from
the International Collaboration on Ovarian Neoplasms (ICON7) phase 3 randomised trial. Lancet Oncol. 2013;14:236-243.
43. LaFargue CJ, Dal Molin GZ, Sood AK, et al. Exploring and comparing adverse events between PARP inhibitors. Lancet Oncol. 2019;20:e15-e28.
44. Dhani NC, Oza AM. Targeting angiogenesis: taming the medusa of ovarian cancer. Hematol Oncol Clin North Am. 2018;32:1041-1055.
45. du Bois A, Floquet A, Kim JW, et al. Incorporation of pazopanib in maintenance therapy of ovarian cancer. J Clin Oncol. 2014;32:3374-3382.
46. du Bois A, Kristensen G, Ray-Coquard I, et al.; AGO Study Group led Gynecologic Cancer Intergroup/European Network of Gynaecologic Oncology Trials Groups
Intergroup Consortium. Standard ﬁrst-line chemotherapy with or without nintedanib for advanced ovarian cancer (AGO-OVAR 12): a randomised, double-blind,
placebo-controlled phase 3 trial. Lancet Oncol. 2016;17:78-89.
47. Kerbel RS, Kamen BA. The anti-angiogenic basis of metronomic chemotherapy. Nat Rev Cancer. 2004;4:423-436.
48. Chan JK, Brady MF, Penson RT, et al. Weekly vs. every-3-week paclitaxel and carboplatin for ovarian cancer. N Engl J Med. 2016;374:738-748.
49. Katsumata N, Yasuda M, Isonishi S, et al.; Japanese Gynecologic Oncology Group. Long-term results of dose-dense paclitaxel and carboplatin versus
conventional paclitaxel and carboplatin for treatment of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (JGOG 3016): a randomised,
controlled, open-label trial. Lancet Oncol. 2013;14:1020-1026.
50. Clamp AR, McNeish I, Dean A, et al. ICON8: a GCIG phase III randomised trial evaluating weekly dose-dense chemotherapy integration in ﬁrst-line epithelial
ovarian/fallopian tube/primary peritoneal carcinoma (EOC) treatment: results of primary progression-free survival (PFS) analysis. Ann Oncol. 2017;28 (suppl 5;
abstr 929O_PR).
51. Pignata S, Scambia G, Katsaros D, et al.; Gynecologic Cancer InterGroup (GCIG) Investigators. Carboplatin plus paclitaxel once a week versus every 3 weeks in
patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trial. Lancet Oncol. 2014;15:396-405.
52. Aghajanian C, Goff B, Nycum LR, et al. Final overall survival and safety analysis of OCEANS, a phase 3 trial of chemotherapy with or without bevacizumab in
patients with platinum-sensitive recurrent ovarian cancer. Gynecol Oncol. 2015;139:10-16.
Maintenance Treatments and Chemotherapy Holidays in Gynecologic Cancers
2019 ASCO EDUCATIONAL BOOK | asco.org/edbook e163
Downloaded from ascopubs.org by University Health Network on May 23, 2019 from 205.189.058.087
Copyright © 2019 American Society of Clinical Oncology. All rights reserved.
53. Coleman RL, Brady MF, Herzog TJ, et al. Bevacizumab and paclitaxel-carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive
ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2017;
18:779-791.
54. Ledermann JA, Embleton AC, Raja F, et al.; ICON6 collaborators. Cediranib in patients with relapsed platinum-sensitive ovarian cancer (ICON6): a randomised,
double-blind, placebo-controlled phase 3 trial. Lancet. 2016;387:1066-1074.
55. Ledermann JA, Embleton AC, Perren T, et al. Overall survival results of ICON6: a trial of chemotherapy and cediranib in relapsed ovarian cancer. J Clin Oncol.
2017;35 (suppl; abstr 5506).
56. Pignata S, Lorusso D, Joly F, et al. Chemotherapy plus or minus bevacizumab for platinum-sensitive ovarian cancer patients recurring after a bevacizumab
containing ﬁrst line treatment: the randomized phase 3 trial MITO16B-MaNGO OV2B-ENGOT OV17. J Clin Oncol. 2018;36 (suppl; abstr 5506).
57. Ledermann J, Harter P, Gourley C, et al. Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. N Engl J Med. 2012;366:1382-1392.
58. Ledermann JA, Harter P, Gourley C, et al. Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance
monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial. Lancet Oncol. 2016;17:1579-1589.
59. Oza AM, Cibula D, Benzaquen AO, et al. Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial.
Lancet Oncol. 2015;16:87-97.
60. Fabbro M, Moore KN, Dørum A, et al. Efﬁcacy and safety of niraparib as maintenance treatment in older patients (≥ 70 years) with recurrent ovarian cancer:
results from the ENGOT-OV16/NOVA trial. Gynecol Oncol. 2019;152:560-567.
61. Oza AM, Matulonis UA, Malander S, et al. Quality of life in patients with recurrent ovarian cancer treated with niraparib versus placebo (ENGOT-OV16/NOVA):
results from a double-blind, phase 3, randomised controlled trial. Lancet Oncol. 2018;19:1117-1125.
62. Lynparza (olaparib) tablets, for oral use [highlights of prescribing information]. Gaithersburg, MD: AstraZeneca Pharmaceuticals LP; 2018.
63. European Medicines Agency. Olaparib (Lynparza). AstraZeneca; 2018. https://www.ema.europa.eu/en/medicines/human/EPAR/lynparza. Accessed January
2019.
64. Zejula (niraparib) capsules, for oral use [highlights of prescribing information]. Waltham, MA: TESARO Inc; 2018.
65. European Medicines Agency. Niraparib (Zejula). TESARO; 2019. https://www.ema.europa.eu/en/medicines/human/EPAR/zejula. Accessed January 2019.
66. Rubraca (rucaparib) tablets, for oral use [highlights of prescribing information]. Boulder, CO: Clovis Oncology Inc; 2018.
67. European Medicines Agency. Rucaparib (Rubraca). Clovis Oncology; 2018. https://www.ema.europa.eu/en/medicines/human/EPAR/rubraca. Accessed
January 2019.
68. Lee DH. Treatments for EGFR-mutant non-small cell lung cancer (NSCLC): the road to a success, paved with failures. Pharmacol Ther. 2017;174:1-21.
69. Ang JE, Gourley C, Powell CB, et al. Efﬁcacy of chemotherapy in BRCA1/2 mutation carrier ovarian cancer in the setting of PARP inhibitor resistance: a multi-
institutional study. Clin Cancer Res. 2013;19:5485-5493.
70. Patch AM, Christie EL, Etemadmoghadam D, et al.; Australian Ovarian Cancer Study Group. Whole-genome characterization of chemoresistant ovarian cancer
[published correction appears in Nature. 2015;527:398]. Nature. 2015;521:489-494.
71. Kondrashova O, Nguyen M, Shield-Artin K, et al.; AOCS Study Group. Secondary somatic mutations restoring RAD51C and RAD51D associated with acquired
resistance to the PARP inhibitor rucaparib in high-grade ovarian carcinoma. Cancer Discov. 2017;7:984-998.
72. Noordermeer SM, Adam S, Setiaputra D, et al. The shieldin complex mediates 53BP1-dependent DNA repair. Nature. 2018;560:117-121.
73. Neyt M, Vlayen J, Devriese S, et al. First- and second-line bevacizumab in ovarian cancer: a Belgian cost-utility analysis. PLoS One. 2018;13:e0195134.
74. ten Bokkel Huinink W, Gore M, Carmichael J, et al. Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer. J Clin Oncol. 1997;
15:2183-2193.
75. MarkmanM, Blessing J, Rubin SC, et al.; Gynecologic Oncology Group. Phase II trial of weekly paclitaxel (80 mg/m2) in platinum and paclitaxel-resistant ovarian
and primary peritoneal cancers: a Gynecologic Oncology Group study. Gynecol Oncol. 2006;101:436-440.
76. Rosenberg P, Andersson H, Boman K, et al. Randomized trial of single agent paclitaxel given weekly versus every three weeks and with peroral versus
intravenous steroid premedication to patients with ovarian cancer previously treated with platinum. Acta Oncol. 2002;41:418-424.
77. Wozniak KM, Vornov JJ, Wu Y, et al. Peripheral neuropathy induced by microtubule-targeted chemotherapies: insights into acute injury and long-term recovery.
Cancer Res. 2018;78:817-829.
78. De Souza R, Zahedi P, Badame RM, et al. Chemotherapy dosing schedule inﬂuences drug resistance development in ovarian cancer. Mol Cancer Ther. 2011;
10:1289-1299.
79. Vassileva V, Allen CJ, Piquette-Miller M. Effects of sustained and intermittent paclitaxel therapy on tumor repopulation in ovarian cancer. Mol Cancer Ther. 2008;
7:630-637.
80. Gordon AN, Fleagle JT, Guthrie D, et al. Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus
topotecan. J Clin Oncol. 2001;19:3312-3322.
81. Gordon AN, Tonda M, Sun S, et al.; Doxil Study 30-49 Investigators. Long-term survival advantage for women treated with pegylated liposomal doxorubicin
compared with topotecan in a phase 3 randomized study of recurrent and refractory epithelial ovarian cancer. Gynecol Oncol. 2004;95:1-8.
82. Kesterson JP, Odunsi K, Lele S. High cumulative doses of pegylated liposomal doxorubicin are not associated with cardiac toxicity in patients with gynecologic
malignancies. Chemotherapy. 2010;56:108-111.
Madariaga et al
e164 2019 ASCO EDUCATIONAL BOOK | asco.org/edbook
Downloaded from ascopubs.org by University Health Network on May 23, 2019 from 205.189.058.087
Copyright © 2019 American Society of Clinical Oncology. All rights reserved.
83. Safra T. Cardiac safety of liposomal anthracyclines. Oncologist. 2003;8(suppl 2):17-24.
84. Paleari L, Gandini S, Provinciali N, et al. Clinical beneﬁt and risk of death with endocrine therapy in ovarian cancer: a comprehensive review and meta-analysis.
Gynecol Oncol. 2017;146:504-513.
85. Hurteau JA, Brady MF, Darcy KM, et al. Randomized phase III trial of tamoxifen versus thalidomide in women with biochemical-recurrent-only epithelial ovarian,
fallopian tube or primary peritoneal carcinoma after a complete response to ﬁrst-line platinum/taxane chemotherapy with an evaluation of serum vascular
endothelial growth factor (VEGF): a Gynecologic Oncology Group study. Gynecol Oncol. 2010;119:444-450.
86. Eeles RA, Morden JP, Gore M, et al. Adjuvant hormone therapy may improve survival in epithelial ovarian cancer: results of the AHT randomized trial. J Clin
Oncol. 2015;33:4138-4144.
87. Grabowski JP, Harter P, Heitz F, et al. Operability and chemotherapy responsiveness in advanced low-grade serous ovarian cancer. An analysis of the AGO
Study Group metadatabase. Gynecol Oncol. 2016;140:457-462.
88. Escobar J, Klimowicz AC, Dean M, et al. Quantiﬁcation of ER/PR expression in ovarian low-grade serous carcinoma. Gynecol Oncol. 2013;128:371-376.
89. Gershenson DM, Bodurka DC, Coleman RL, et al. Hormonal maintenance therapy for women with low-grade serous cancer of the ovary or peritoneum. J Clin
Oncol. 2017;35:1103-1111.
90. Long HJ 3rd, Bundy BN, Grendys EC Jr, et al.; Gynecologic Oncology Group Study. Randomized phase III trial of cisplatin with or without topotecan in carcinoma
of the uterine cervix: a Gynecologic Oncology Group study. J Clin Oncol. 2005;23:4626-4633.
91. Moore DH, Blessing JA, McQuellon RP, et al. Phase III study of cisplatin with or without paclitaxel in stage IVB, recurrent, or persistent squamous cell carcinoma
of the cervix: a gynecologic oncology group study. J Clin Oncol. 2004;22:3113-3119.
92. Monk BJ, Sill MW, McMeekin DS, et al. Phase III trial of four cisplatin-containing doublet combinations in stage IVB, recurrent, or persistent cervical carcinoma:
a Gynecologic Oncology Group study. J Clin Oncol. 2009;27:4649-4655.
93. Tewari KS, Sill MW, Penson RT, et al. Bevacizumab for advanced cervical cancer: ﬁnal overall survival and adverse event analysis of a randomised, controlled,
open-label, phase 3 trial (Gynecologic Oncology Group 240). Lancet. 2017;390:1654-1663.
94. Kandula T, Farrar MA, Cohn RJ, et al. Chemotherapy-induced peripheral neuropathy in long-term survivors of childhood cancer: clinical, neurophysiological,
functional, and patient-reported outcomes. JAMA Neurol. 2018;75:980-988.
95. Latcha S, Jaimes EA, Patil S, et al. Long-term renal outcomes after cisplatin treatment. Clin J Am Soc Nephrol. 2016;11:1173-1179.
96. Bestvina CM, Fleming GF. Chemotherapy for endometrial cancer in adjuvant and advanced disease settings. Oncologist. 2016;21:1250-1259.
97. Lee YC, Lheureux S, Oza AM. Treatment strategies for endometrial cancer: current practice and perspective. Curr Opin Obstet Gynecol. 2017;29:47-58.
98. McMeekin DS, Filiaci VL, Thigpen JT, et al.; Gynecologic Oncology Group study. The relationship between histology and outcome in advanced and recurrent
endometrial cancer patients participating in ﬁrst-line chemotherapy trials: a Gynecologic Oncology Group study. Gynecol Oncol. 2007;106:16-22.
99. Sagae S, SusumuN, Viswanathan AN, et al. Gynecologic Cancer InterGroup (GCIG) consensus review for uterine serous carcinoma. Int J Gynecol Cancer. 2014;
24(suppl 3):S83-S89.
100. Fleming GF, Brunetto VL, Cella D, et al. Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus ﬁlgrastim in advanced endometrial carcinoma:
a Gynecologic Oncology Group study. J Clin Oncol. 2004;22:2159-2166.
101. Miller D, Filiaci V, Fleming G, et al. Randomized phase III noninferiority trial of ﬁrst line chemotherapy for metastatic or recurrent endometrial carcinoma:
a Gynecologic Oncology Group study. Gynecol Oncol. 2012;125 (abstr 771).
102. Simpkins F, Drake R, Escobar PF, et al. A phase II trial of paclitaxel, carboplatin, and bevacizumab in advanced and recurrent endometrial carcinoma (EMCA).
Gynecol Oncol. 2015;136:240-245.
103. Aghajanian C, Filiaci V, Dizon DS, et al. A phase II study of frontline paclitaxel/carboplatin/bevacizumab, paclitaxel/carboplatin/temsirolimus, or ixabepilone/
carboplatin/bevacizumab in advanced/recurrent endometrial cancer. Gynecol Oncol. 2018;150:274-281.
104. Fader AN, Roque DM, Siegel E, et al. Randomized phase II trial of carboplatin-paclitaxel versus carboplatin-paclitaxel-trastuzumab in uterine serous carcinomas
that overexpress human epidermal growth factor receptor 2/neu. J Clin Oncol. 2018;36:2044-2051.
105. D’Angelo E, Prat J. Uterine sarcomas: a review. Gynecol Oncol. 2010;116:131-139.
106. Pervaiz N, Colterjohn N, Farrokhyar F, et al. A systematic meta-analysis of randomized controlled trials of adjuvant chemotherapy for localized resectable soft-
tissue sarcoma. Cancer. 2008;113:573-581.
107. Patel SR, Vadhan-Raj S, Papadopolous N, et al. High-dose ifosfamide in bone and soft tissue sarcomas: results of phase II and pilot studies--dose-response and
schedule dependence. J Clin Oncol. 1997;15:2378-2384.
108. Seddon B, Strauss SJ, Whelan J, et al. Gemcitabine and docetaxel versus doxorubicin as ﬁrst-line treatment in previously untreated advanced unresectable or
metastatic soft-tissue sarcomas (GeDDiS): a randomised controlled phase 3 trial. Lancet Oncol. 2017;18:1397-1410.
109. Elias A, Ryan L, Sulkes A, et al. Response to mesna, doxorubicin, ifosfamide, and dacarbazine in 108 patients with metastatic or unresectable sarcoma and no
prior chemotherapy. J Clin Oncol. 1989;7:1208-1216.
110. van der Graaf WT, Blay JY, Chawla SP, et al.; PALETTE study group. Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind,
placebo-controlled phase 3 trial. Lancet. 2012;379:1879-1886.
111. Demetri GD, von Mehren M, Jones RL, et al. Efﬁcacy and safety of trabectedin or dacarbazine for metastatic liposarcoma or leiomyosarcoma after failure of
conventional chemotherapy: results of a phase III randomized multicenter clinical trial. J Clin Oncol. 2016;34:786-793.
Maintenance Treatments and Chemotherapy Holidays in Gynecologic Cancers
2019 ASCO EDUCATIONAL BOOK | asco.org/edbook e165
Downloaded from ascopubs.org by University Health Network on May 23, 2019 from 205.189.058.087
Copyright © 2019 American Society of Clinical Oncology. All rights reserved.
112. Phippen NT, Leath CA 3rd, Havrilesky LJ, et al. Bevacizumab in recurrent, persistent, or advanced stage carcinoma of the cervix: is it cost-effective? Gynecol
Oncol. 2015;136:43-47.
113. Swisher EM, Lin KK, Oza AM, et al. Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 part 1): an international, multicentre,
open-label, phase 2 trial. Lancet Oncol. 2017;18:75-87.
114. Collinson F, Hutchinson M, Craven RA, et al. Predicting response to bevacizumab in ovarian cancer: a panel of potential biomarkers informing treatment
selection. Clin Cancer Res. 2013;19:5227-5239.
Madariaga et al
e166 2019 ASCO EDUCATIONAL BOOK | asco.org/edbook
Downloaded from ascopubs.org by University Health Network on May 23, 2019 from 205.189.058.087
Copyright © 2019 American Society of Clinical Oncology. All rights reserved.
